Around the Region

Cubist’s antibiotic on fast track

Federal regulators have granted fast-track review status­ of several uses for an experimental­ antibiotic drug developed by Cubist Pharmaceuticals Inc.

The Lexington company said it got fast-track status from the Food and Drug Administration­ for ceftolozane/tazobactam, also known as CXA-201, in treating hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia, along with complicated urinary tract infections.

In February, the FDA granted fast-track status for CXA-201 in treating complex intra-abdominal infections.


If the drug is approved under the priority review, Cubist will get a five-year extension of exclusivity under an antibiotics incentive law signed by President Obama last year.

Robert Weisman

Robert Weisman can be reached at Follow him on Twitter @GlobeRobW.